Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2011

01-02-2011 | Original Article

Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection

Authors: Kojun Okamoto, Isamu Koyama, Mitsuo Miyazawa, Yasuko Toshimitsu, Masayasu Aikawa, Katsuya Okada, Etsuko Imabayashi, Hiroshi Matsuda

Published in: International Journal of Clinical Oncology | Issue 1/2011

Login to get access

Abstract

Background

An important step in deciding the treatment strategy for pancreatic cancer is to preoperatively predict the possibility of early recurrence. We reviewed whether 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) before pancreatic cancer resection could predict tumor recurrence in the early postoperative period.

Methods

FDG-PET/CT was performed preoperatively on 56 patients with pancreatic cancer. The maximum standardized uptake (SUVmax) values obtained by FDG-PET/CT were compared between two groups: patients with and without recurrence within the first 6 postoperative months. SUVmax analyses were also performed to determine whether age, sex, CA 19-9 values, the operative method, and portal vein resection were also predictive of recurrence within less than 6 months after tumor resection.

Results

The median SUVmax values of the recurrence group and no-recurrence group were 7.9 and 4.2, respectively (P = 0.0042). The SUVmax was the only risk factor for recurrence in the first 6 postoperative months identified by multivariate analysis (P = 0.0062).

Conclusions

Preoperative SUVmax was higher in the recurrence group during the early postoperative period, and a high SUVmax was a risk factor for early postoperative recurrence. Based on these results, we conclude that FDG-PET/CT is predictive of the recurrence of pancreatic cancer in the early postoperative period.
Literature
1.
Satoi S, Yanagimoto H, Toyokawa H et al (2009) Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 38:282–288CrossRefPubMed
2.
Takai S, Satoi S, Yanagimoto H et al (2008) Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas 36:e26–e32CrossRefPubMed
3.
Wilkowski R, Wolf M, Heinemann V (2008) Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res 177:79–93CrossRefPubMed
4.
Wilkowski R, Thoma M, Bruns C et al (2006) Chemoradiotherapy with gemcitabine and continuous 5-Fu in patients with primary inoperable pancreatic cancer. JOP 7:349–360PubMed
5.
Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297:267–277CrossRefPubMed
6.
Japan Pancreas Society (2009) General rules for the study of pancreatic cancer, 6th edn. Kanehara, Tokyo
7.
Friess H, Langhans J, Ebert HG et al (1995) Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-d-glucose positron emission tomography. Gut 36:771–777CrossRefPubMed
8.
Stollfuss JC, Glatting G, Friess H et al (1995) 2-(fluorine-18)-Fluoro-2-deoxy-d-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 195:339–344PubMed
9.
Koyama K, Okamura T, Kawabe J et al (2001) Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15:217–224CrossRefPubMed
10.
Higashi T, Tamaki N, Honda T et al (1997) Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38:1337–1344PubMed
11.
Lee JD, Yang WI, Park YN et al (2005) Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increase (18)F-FDG uptake. J Nucl Med 46:1753–1759PubMed
12.
Higashi T, Saga T, Nakamoto Y et al (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173–180PubMed
13.
Vansteenkiste JF, Stroobants SG, Dupont PJ et al (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: analysis of 125 cases. J Clin Oncol 17:3201–3206PubMed
14.
Downey RJ, Akhurst T, Gonen M et al (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255–3260CrossRefPubMed
15.
Cerfolio RJ, Bryant AS, Ohja B et al (2005) The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130:151–159CrossRefPubMed
16.
Rizk N, Downey RJ, Akhurst T et al (2006) Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 81:1076–1081CrossRefPubMed
17.
Wakabayashi H, Nishiyama Y, Otani T et al (2008) Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14:64–69CrossRefPubMed
18.
van Kouwen MC, Jansen JB, van Goor H et al (2005) FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 32:399–404CrossRefPubMed
19.
Seo S, Doi R, Machimoto T et al (2008) Contribution of 18F-fluorodexyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg 15:634–639CrossRefPubMed
20.
Delbeke D, Pinson CW (2004) Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 11:4–10CrossRefPubMed
21.
Parson CM, Sutcliffe JL, Bold RJ (2008) Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 15:429–435CrossRef
22.
Maemura K, Takao S, Shinchi H et al (2006) Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 13:435–441CrossRefPubMed
23.
Doi R, Imamura M, Hosotani R et al (2008) Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today 38:1021–1028CrossRefPubMed
24.
Imamura M, Doi R, Imaizumi T et al (2004) A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 136:1003–1011CrossRefPubMed
25.
Showalter TN, Rao AS, Rani Anne P et al (2009) Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol 16:2116–2122CrossRefPubMed
26.
Ogawa K, Karasawa K, Ito Y et al (2010) Intraoperative radiotherapy for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 3:734–742
27.
Choi M, Heilbrun LK, Venkatramanamoorthy R et al (2010) Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33:257–261PubMed
28.
Wieder HA, Ott K, Lordick F et al (2007) Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 34:1925–1932CrossRefPubMed
29.
Farrag A, Ceulemans G, Voordeckers M et al (2010) Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 31:495–501PubMed
Metadata
Title
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection
Authors
Kojun Okamoto
Isamu Koyama
Mitsuo Miyazawa
Yasuko Toshimitsu
Masayasu Aikawa
Katsuya Okada
Etsuko Imabayashi
Hiroshi Matsuda
Publication date
01-02-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0124-z

Other articles of this Issue 1/2011

International Journal of Clinical Oncology 1/2011 Go to the issue

Case Report

Gastrectomy and chemotherapy with S-1 for gastric cancer in a patient with acquired immunodeficiency syndrome

Original Article

Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy

Original Article

Primary fallopian tube carcinoma: a clinicopathological analysis of a rare entity

Case Report

Primary intracranial leiomyosarcoma in an HIV-infected patient

Introduction To Review Articles

Oral premalignant lesions

Case Report

A radio-sensitive primary osteosarcoma in the lung
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits